Inhibrx Biosciences (INBX) Share-based Compensation (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of Share-based Compensation data on file, last reported at $2.7 million in Q4 2025.

• On a quarterly basis, Share-based Compensation fell 8.01% year-over-year to $2.7 million in Q4 2025; TTM through Dec 2025 was $8.0 million, a 85.67% decrease from a year earlier, with the FY2025 full-year figure at $11.1 million, down 80.97% from the prior year.
• Share-based Compensation for Q4 2025 stood at $2.7 million, down from $2.8 million in the prior quarter.
• Over the last five years, Share-based Compensation for INBX reached as high as $46.2 million in Q2 2024 and fell as low as $2.4 million in Q1 2025.
• Historically, Share-based Compensation has averaged $9.6 million across 3 years, with a median of $4.7 million in 2024.
• On a YoY basis, Share-based Compensation climbed as much as 8.01% in 2025 and fell as far as 94.0% in 2025.
• Year by year, Share-based Compensation stood at $6.4 million in 2023, then plunged by 53.6% to $3.0 million in 2024, then slipped by 8.01% to $2.7 million in 2025.
• Per Business Quant data, the three most recent Share-based Compensation figures were $2.7 million in Q4 2025, $2.8 million in Q2 2025, and $2.4 million in Q1 2025.